Testing two antibiotics against resistant lung and bloodstream infections
Treatments studied
Part of Infections clinical trials.
This trial studies whether cefiderocol plus ampicillin-sulbactam works better than colistin (sometimes with meropenem) for serious infections caused by carbapenem-resistant Acinetobacter baumannii (a hard-to-treat germ). It may help by finding a more effective antibiotic plan for people with these severe hospital-acquired infections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult over 18 years old
- You have a serious infection in the blood (bacteremia) or pneumonia from a hospital or breathing machine (HAP/VAP)
- The infection is caused by carbapenem-resistant Acinetobacter baumannii, confirmed in lab tests
- The germ must be likely to respond to cefiderocol based on test results (an MIC less than 2, or a disc test result at least 17 mm)
- You have not already had more than 72 hours of antibiotics that would cover this resistant germ in the first 96 hours after enrolling
- You are not pregnant, and you can give consent (including delayed/deferred consent if allowed locally)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests different antibiotic combinations for severe infections caused by hard-to-treat Gram-negative bacteria (like Pseudomonas or Acinetobacter). The goal is to find the best treatment for bloodstream infections or pneumonia that started in the hospital.
This trial tests two different antibiotic combinations (ampicillin/sulbactam and cefoperazone/sulbactam) to see which works better against a type of bacteria (Acinetobacter baumannii) that is resistant to many other drugs. It is for critically ill patients with signs of sepsis.
This trial tests a combination of two antibiotics (meropenem and pralurbactam) for treating serious infections caused by bacteria that are resistant to many other antibiotics. It may be an option for hospitalized patients with pneumonia, urinary tract infections, abdominal infections, or bloodstream infections.
This trial compares a new antibiotic (BV100 plus low-dose polymyxin B) against a standard treatment for pneumonia caused by a hard-to-treat bacteria (Acinetobacter baumannii). If you have hospital-acquired or ventilator-associated pneumonia and standard antibiotics aren't working, this study may offer a new option.
This trial compares different treatment options for patients in the ICU who have a resistant bacterial infection called Acinetobacter baumannii. If you have this infection after surgery, the study aims to find the best way to treat it.
This trial tests a combination of antibiotics (BV100, polymyxin B, and either ceftazidime/avibactam or cefiderocol) for serious lung or bloodstream infections caused by a tough-to-treat bacteria called Acinetobacter. The goal is to see if the combination is safe and works better than current treatments.
Hear when a new Carbapenem Resistant Bacterial Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.